Overview

Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA

Status:
Unknown status

Trial end date:
2018-07-01

Target enrollment:

Participant gender:

Summary

This is an open label, multi-center, single arm phase II study. The study will investigate the efficacy of sodium cridanimod in conjunction with progestin therapy in a population of patients with recurrent or persistent PrR-negative endometrial cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Kevelt AS

Collaborator:

Pharmasyntez

Treatments:

10-carboxymethyl-9-acridanone
Medroxyprogesterone
Medroxyprogesterone Acetate
Megestrol Acetate
Progesterone
Progestins